Literature DB >> 15724267

The withdrawal of rofecoxib.

Félix M Arellano1.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2005        PMID： 15724267     DOI： 10.1002/pds.1077

Source DB:  PubMed          Journal:  Pharmacoepidemiol Drug Saf        ISSN： 1053-8569            Impact factor:   2.890


× No keyword cloud information.
  7 in total

1.  Prescriptions for selective cyclooxygenase-2 inhibitors, non-selective non-steroidal anti-inflammatory drugs, and risk of breast cancer in a population-based case-control study.

Authors:  Deirdre P Cronin-Fenton; Lars Pedersen; Timothy L Lash; Søren Friis; John A Baron; Henrik T Sørensen
Journal:  Breast Cancer Res       Date:  2010-03-01       Impact factor: 6.466

2.  Was the thrombotic risk of rofecoxib predictable from the French Pharmacovigilance Database before 30 September 2004?

Authors:  A Sommet; S Grolleau; H Bagheri; M Lapeyre-Mestre; J L Montastruc
Journal:  Eur J Clin Pharmacol       Date:  2008-05-29       Impact factor: 2.953

3.  Medication-wide association studies.

Authors:  P B Ryan; D Madigan; P E Stang; M J Schuemie; G Hripcsak
Journal:  CPT Pharmacometrics Syst Pharmacol       Date:  2013-09-18

4.  Meta-analysis of the related nutritional supplements dimethyl sulfoxide and methylsulfonylmethane in the treatment of osteoarthritis of the knee.

Authors:  Sarah Brien; Phil Prescott; George Lewith
Journal:  Evid Based Complement Alternat Med       Date:  2011-02-17       Impact factor: 2.629

5.  Finding multiple target optimal intervention in disease-related molecular network.

Authors:  Kun Yang; Hongjun Bai; Qi Ouyang; Luhua Lai; Chao Tang
Journal:  Mol Syst Biol       Date:  2008-11-04       Impact factor: 11.429

6.  Actions following adverse drug events - how do these influence uptake and utilisation of newer and/or similar medications?

Authors:  Nadia Barozzi; G M E E Geeske Peeters; Susan E Tett
Journal:  BMC Health Serv Res       Date:  2015-11-06       Impact factor: 2.655

7.  Assessing the effects of non-steroidal anti-inflammatory drugs on antihypertensive drug therapy using post-marketing surveillance database.

Authors:  Chieko Ishiguro; Toshiharu Fujita; Takashi Omori; Yosuke Fujii; Takeshi Mayama; Tosiya Sato
Journal:  J Epidemiol       Date:  2008-05-09       Impact factor: 3.211
  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.